Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir

MLA

Bandar Alosaimi, et al. “Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.” Pharmaceuticals, vol. 15, no. 12, Nov. 2022, p. 1456. EBSCOhost, https://doi.org/10.3390/ph15121456.

APA

Bandar Alosaimi, Huda M. Alshanbari, Muath Alturaiqy, Halah Z. AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A. Alrashed, Ahmad Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J. Alshalani, & Wael Alturaiki. (2022). Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals, 15(12), 1456. https://doi.org/10.3390/ph15121456

Chicago

Bandar Alosaimi, Huda M. Alshanbari, Muath Alturaiqy, Halah Z. AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, et al. 2022. “Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.” Pharmaceuticals 15 (12): 1456. doi:10.3390/ph15121456.